Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 1238 • ACR Convergence 2024
Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², seoidin McKittrick³, Robert Harrington⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³University of Limerick, Limerick, Ireland, ⁴St. James's Hospital, Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: One of the most significant unmet needs in the management of those with Polymyalgia Rheumatica (PMR) is the lack of a disease stratification tool…
Abstract Number: 2513 • ACR Convergence 2024
Frequency, Diagnosis, and Management of Polymyalgia Rheumatica in Germany – Database Analysis of Medical Insurance Data
Wolfgang Schmidt¹, Marco Alibone², Paul Ludwig², Dominik Obermüller², Dennis Häckl³, Katrin Tönnessen⁴, Mirjam Fließer⁴, Franziska Karl⁴, Hien Nguyen⁴, Annika Boas⁴ and Nils Venhoff⁵, ¹Immanuel Krankenhaus Berlin, Berlin, Germany, ²InGef-Institute for Applied Health Research Berlin GmbH, Berlin, Germany, ³WIG2 GmbH, Leipzig, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany
Background/Purpose: To date, there is limited data on the epidemiology of polymyalgia rheumatica (PMR) in Germany. National prevalence estimates suggest only 69,000 affected individuals, which…
Abstract Number: 0739 • ACR Convergence 2024
One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic
Patricia Harkins¹, Sharon Cowley², Robert Harrington³, seoidin McKittrick⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³St. James's Hospital, Dublin, Dublin, Ireland, ⁴University of Limerick, Limerick, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: To date the longitudinal outcomes of those with isolated Polymyalgia Rheumatica (PMR) are poorly understood, owing largely to the fact that in the majority…
Abstract Number: 1318 • ACR Convergence 2024
Patient Anxiety, Fear, and Kinesiophobia: Challenges Shared by UK Physiotherapists in Managing Polymyalgia Rheumatica – Findings from a Qualitative Study
Anne O'Brien¹, Sara Muller¹, Jennifer Liddle², Martin Thomas¹ and Christian D Mallen³, ¹Keele University, Keele, Staffordshire, England, United Kingdom, ²Newcastle University, Newcastle upon Tyne, United Kingdom, ³Keele University, Keele, Staffordshire, United Kingdom
Background/Purpose: Polymyalgia Rheumatica (PMR) is the commonest rheumatic condition affecting older people. 35% of newly diagnosed patients report anxiety, (Muller et al., 2016) which, with…
Abstract Number: 0740 • ACR Convergence 2024
Evaluation of an Accelerated Physical Aging Phenotype in Newly Diagnosed Patients with Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², seoidin McKittrick³, Robert Harrington⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³University of Limerick, Limerick, Ireland, ⁴St. James's Hospital, Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: Polymyalgia Rheumatica (PMR) is the most common inflammatory rheumatic disease in older adults, and aging has been postulated to be central to its pathophysiology.…
Abstract Number: 1618 • ACR Convergence 2024
Co-occurrence of Giant Cell Arteritis and Polymyalgia Rheumatica: Insights from a Retrospective Analysis
Vivekanand Tiwari¹, chih fang², Emily Campbell³, Katherine loomba², Nisha Khubchandani², shikha shah² and William Rigby⁴, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth Hitchcock Medical Center, Lebanon, ³Dartmouth Health, Lebanon, NH, ⁴Dartmouth-Hitchcock, Norwich, VT
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related conditions that often co-occur.1 Approximately half of all patients with GCA experience PMR…
Abstract Number: 0741 • ACR Convergence 2024
Serum Markers of Disease Activity in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², seoidin McKittrick³, Robert Harrington⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³University of Limerick, Limerick, Ireland, ⁴St. James's Hospital, Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: A significant unmet need in Polymyalgia Rheumatica (PMR) is the lack of a disease specific serum biomarker for diagnosis, and monitoring of disease activity.…
Abstract Number: 1619 • ACR Convergence 2024
Challenges in Managing Polymyalgia Rheumatica and Giant Cell Arteritis: Steroid Dependence and Preventive Care
Vivekanand Tiwari¹, chih fang², Katherine loomba², Nisha Khubchandani², shikha shah² and William Rigby³, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth Hitchcock Medical Center, Lebanon, ³Dartmouth-Hitchcock, Norwich, VT
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…
Abstract Number: 0743 • ACR Convergence 2024
Higher Baseline FDG Musculoskeletal Uptake at PET/CT Is Associated with a Higher Remission Rate in Polymyalgia Rheumatica: A Retrospective 3-year Observational Study
Elvis Hysa¹, Dario Camellino², Cristina Bernini³, Paolo Vittoriano Clini⁴, Matteo Bauckneht⁵, silvia Morbelli⁶, Gianmario Sambuceti⁵, Emanuele Gotelli⁷, Alberto Sulli⁸, Maurizio Cutolo⁷ and Marco Amedeo Cimmino¹, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ²Division of Rheumatology, Local Health Trust 3, Genoa, Italy, ³Emergency Medicine Department, San Martino Polyclinic Hospital, Genoa, Italy,, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Nuclear Medicine Unit and Department of Health Sciences, University of Genova, Genoa, Italy, Genoa, Italy, ⁶University of Torino, Torino, Italy, ⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ⁸Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory diseases characterized by increased musculoskeletal and vascular uptakes of 18-Fluorodeoxyglucose (18F-FDG) at positron…
Abstract Number: 1622 • ACR Convergence 2024
18F-FDG PET/CT in LVV During Active and Inactive Disease Phases Is Associated with the Metabolic Profile, but Not with Macrophage-related Cytokines: Results of an Integrated Analysis
Dimitrios Anastasios Palamidas¹, Georgios Kalykakis², Dimitra Benaki³, Loukas chatzis¹, Ourania Argyropoulou⁴, Panagiota Palla⁴, Antonia Kollia⁵, Pavlos Kafouris⁵, Marinos Metaxas⁵, Andreas Goules⁶, Emmanuel Mikros⁷, Konstantinos Kambas⁸, Constantinos Anagnostopoulos⁵ and Athanasios Tzioufas⁹, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Department of Informatics, Ionian University, Kerkyra, Greece, Athens, Greece, ³Department of Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁴Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁵PET-CT Department & Preclinical Imaging Unit, Center for Experimental Surgery, Clinical & Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece., Athens, Greece, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁷Department of Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁸Laboratory of Molecular Genetics, Department of Immunology, Hellenic Pasteur Institute, Athens, Greece., Athens, Greece, ⁹LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Giant cell arteritis (GCA) may affect temporal arteries (cranial-GCA) or may present as a systemic disease extended to the large vessels [Large Vessel Vasculitis…
Abstract Number: 0747 • ACR Convergence 2024
Clofutriben to Improve the Benefit-Risk Profile of Prednisolone in Patients with Polymyalgia Rheumatica
FRANK HARTMUT DR. BUTTGEREIT¹, Andrea Everding², Ioana Andreica³, Herbert Kellner⁴, Florian Schuch⁵, Tonya K Marmon⁶, Frank S Czerwiec⁷, Ketan Desai⁸ and David A Katz⁹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Hamburger Rheuma Forschungszentrum II, Hamburg, Germany, ³Rheumazentrum Ruhrgebiet, Bochum, Germany, ⁴Schwerpunktpraxis f�r Rheumatologie und Gastroenterologie, Munich, Germany, ⁵PGRN, Erlangen, Germany, ⁶Marmon Biostatistics, Seattle, WA, ⁷Sparrow Pharmaceuticals, Portand, OR, ⁸IMC, Easton, PA, ⁹Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) differentially regulates intracellular glucocorticoid levels in the immune system and glucocorticoid toxicity target organs. Clofutriben is a potent HSD-1…
Abstract Number: 1629 • ACR Convergence 2024
Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica Has a Different Vascular Ultrasound Phenotype Than Giant Cell Arteritis
Sharon Cowley¹, Patricia Harkins², Colm Kirby³, Richard Conway⁴, David Kane⁵, Rositsa Karalilova⁶, Pierluigi Macchioni⁷, Christina Ponte⁸, Edoardo Conticini⁹, Alessandro Tomelleri¹⁰, Sara Monti¹¹, irene monjo¹², Zguro Batalov¹³, Giulia Klinowski⁷, Paolo Falsetti¹⁴, Corrado Campochiaro¹⁵, Alojzija Hocevar¹⁶ and Eugenio De Miguel¹⁷, ¹Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ²Trinity College Dublin, Dublin 8, Dublin, Ireland, ³Tallaght University Hospital, DUBLIN, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, Plovdiv, Bulgaria, ⁷Rheumatology Department, Ospedale S Maria Nuova, Reggio Emilia, Italy, Emilia, Italy, ⁸Rheumatology, Centro Hospitalar Universitario Lisboa Norte EPE, Lisboa, Portugal, Lisboa, Portugal, ⁹Università di Siena, Siena, Italy, ¹⁰Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy, ¹¹IRCCS Istituto Auxologico Italiano, Milan, Italy, ¹²University Hospital La Paz, Madrid, Spain, ¹³Rheumatology, University Hospital Kaspela, Plovdiv, Bulgaria, Plovdiv, Bulgaria, ¹⁴Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy, Siena, Italy, ¹⁵IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹⁶University Medical Center Ljubljana, LJUBLJANA, Slovenia, ¹⁷Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Subclinical GCA in PMR has been estimated to affect 1 in 5 patients as assessed by vascular ultrasound [1, 2]. This study compared the ultrasound…
Abstract Number: 0748 • ACR Convergence 2024
Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Sebastian E. Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Massachusetts General Hospital, Winchester, MA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment of polymyalgia rheumatica (PMR) is hindered by lack of glucocorticoid (GC)-sparing therapies with proven efficacy. A retrospective study showed a higher proportion of…
Abstract Number: 1637 • ACR Convergence 2024
Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Pablo Muñoz Martínez¹, Claudia Fernandez Ruiz², Elena Grau García³, Samuel Leal Rodriguez³, José Ivorra-Cortés⁴, Carmen Riesco Barcena⁵, Anderson Huaylla Quispe⁵, Laura Mas Sánchez⁶, Daniel Ramos Castro⁵, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado⁵ and Jose A Román-Ivorra⁹, ¹Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ²Escuela de Doctorado. UCV, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Rheumatology Department. HUP La Fe, Valencia, Spain, ⁶Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: The dysregulation of the immune system inherent in inflammatory diseases may contribute to the development of neoplasms. However, the relationship between the giant cell…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.